<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00047281</url>
  </required_header>
  <id_info>
    <org_study_id>01-278</org_study_id>
    <secondary_id>P30CA006516</secondary_id>
    <secondary_id>CDR0000257584</secondary_id>
    <secondary_id>NCI-G02-2117</secondary_id>
    <secondary_id>CELGENE-2001-P-001757/3</secondary_id>
    <nct_id>NCT00047281</nct_id>
  </id_info>
  <brief_title>Thalidomide, Celecoxib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Malignant Glioma</brief_title>
  <official_title>Trial Of Oral Thalidomide, Celecoxib, Etoposide And Cyclophosphamide In Adult Patients With Relapsed Or Progressive Malignant Gliomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Schering-Plough</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Thalidomide and celecoxib may stop the growth of tumor cells by stopping blood&#xD;
      flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from&#xD;
      dividing so they stop growing or die. Combining thalidomide and celecoxib with etoposide and&#xD;
      cyclophosphamide may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of combining thalidomide and celecoxib&#xD;
      with etoposide and cyclophosphamide in treating patients who have relapsed or refractory&#xD;
      malignant glioma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the efficacy of thalidomide, celecoxib, etoposide, and cyclophosphamide, in&#xD;
           terms of 6-month progression-free survival, in patients with relapsed or refractory&#xD;
           malignant glioma.&#xD;
&#xD;
        -  Determine the overall survival of patients treated with this regimen.&#xD;
&#xD;
        -  Determine the toxic effects of this regimen in these patients.&#xD;
&#xD;
        -  Determine the radiographic response in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive oral thalidomide once daily and oral celecoxib twice daily on days 1-42,&#xD;
      oral etoposide once daily on days 1-21, and oral cyclophosphamide once daily on days 22-42.&#xD;
      Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed every 2 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 48 patients (32 with glioblastoma multiforme and 16 with&#xD;
      anaplastic glioma) will be accrued for this study within 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2004</start_date>
  <completion_date type="Actual">February 2006</completion_date>
  <primary_completion_date type="Actual">August 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Brain and Central Nervous System Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>celecoxib</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thalidomide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed intracranial malignant glioma, including glioblastoma&#xD;
             multiforme, gliosarcoma, anaplastic astrocytoma, anaplastic oligodendroglioma,&#xD;
             anaplastic mixed oligoastrocytoma, or malignant astrocytoma not otherwise specified&#xD;
&#xD;
          -  Unequivocal evidence of relapsed or refractory disease by MRI or CT scan and/or tumor&#xD;
             resection&#xD;
&#xD;
               -  Steroid therapy prior to MRI or CT scan must have been at a stable dose for at&#xD;
                  least 5 days&#xD;
&#xD;
               -  Failed prior radiotherapy&#xD;
&#xD;
                    -  Must have confirmation of true progression rather than radiation necrosis if&#xD;
                       previously treated with interstitial brachytherapy or stereotactic&#xD;
                       radiosurgery&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  More than 2 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm3&#xD;
&#xD;
          -  Hemoglobin greater than 9 g/dL&#xD;
&#xD;
          -  No history of bleeding disorder&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin less than 1.5 mg/dL&#xD;
&#xD;
          -  SGPT less than 2.5 times normal&#xD;
&#xD;
          -  Alkaline phosphatase less than 2.5 times normal&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine less than 1.5 times upper limit of normal (ULN) OR&#xD;
&#xD;
          -  BUN less than 1.5 times ULN&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No deep vein thrombosis within the past 3 weeks (must be clinically stable)&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No pulmonary embolism within the past 3 weeks (must be clinically stable)&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No peripheral neuropathy grade 2 or greater&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No other serious concurrent medical illness&#xD;
&#xD;
          -  No concurrent illness that may obscure toxicity or dangerously alter drug metabolism&#xD;
&#xD;
          -  No other malignancy within the past 3 years except nonmelanoma skin cancer or&#xD;
             carcinoma in situ of the cervix&#xD;
&#xD;
          -  Must participate in the System for Thalidomide Education and Prescribing Safety&#xD;
             program&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use 2 forms of effective contraception for 1 month before,&#xD;
             during, and for 1 month after study&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No prior oral thalidomide or celecoxib for more than 2 months duration&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior oral etoposide or cyclophosphamide for more than 2 months duration&#xD;
&#xD;
          -  Prior standard-dose IV etoposide and cyclophosphamide allowed&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Concurrent steroids allowed&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Prior surgery for relapsed or refractory disease allowed&#xD;
&#xD;
          -  Recovered from prior surgery&#xD;
&#xD;
          -  No concurrent surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No other concurrent investigational agents or treatment&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
&#xD;
          -  Concurrent antiseizure medications allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Y. Wen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>October 3, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>July 6, 2017</last_update_submitted>
  <last_update_submitted_qc>July 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Patrick Y. Wen, MD</investigator_full_name>
    <investigator_title>Director, Center for Neuro-Oncology</investigator_title>
  </responsible_party>
  <keyword>adult anaplastic astrocytoma</keyword>
  <keyword>adult anaplastic oligodendroglioma</keyword>
  <keyword>adult glioblastoma</keyword>
  <keyword>adult mixed glioma</keyword>
  <keyword>recurrent adult brain tumor</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Etoposide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

